Abstract
New agents are available for the treatment of metastatic transitional cell carcinoma of the bladder. In the US, the combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) remains the standard chemotherapy regimen for advanced bladder cancer. Gemcitabine (2′,2″-difluorodeoxycytidine [dFdCD is a relatively new agent with a favourable toxicity profile that has demonstrated activity against a number of solid tumours in both preclinical and clinical studies. Single-agent gemcitabine has shown activity in bladder cancer in both pretreated and chemotherapy-naïve patients. The combination of gemcitabine plus cisplatin is a regimen with significant activity and moderate toxicity in bladder cancer patients. A randomised trial of gemcitabine plus cisplatin versus M-VAC has completed accrual but has not yet been reported. New combination studies of gemcitabine with other chemotherapy agents, including the taxanes, are ongoing. 2000
| Original language | English (US) |
|---|---|
| Pages (from-to) | 547-553 |
| Number of pages | 7 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2000 |
| Externally published | Yes |
Keywords
- Antimetabolites
- Bladder cancer
- Cisplatin
- Clinical trials
- Gemcitabine
- Transitional cell carcinoma
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)